Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Listing Social Engagement Event
June 06 2024 - 5:14PM
Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq:
TVGN), is a clinical-stage specialty immunotherapy company
harnessing one of nature’s most powerful immunological weapons,
CD8+ cytotoxic T lymphocytes (“CD8+ CTLs”), to develop
off-the-shelf, precision T cell therapies for the treatment of
infectious diseases, cancers, and neurological disorders with the
aim of addressing the significant unmet needs of large patient
populations.
Tevogen Bio, founded by a group of pioneering industry leaders
and distinguished scientists with extensive drug development and
global product launch experience, aims to chart the next frontier
of medicine, where disruptive science and innovative business
models pave the way to a healthier future for all, centered on the
concept that sustainable business success is intrinsically linked
to societal prosperity. At its inaugural post-public listing social
engagement on May 31, 2024, Tevogen's leadership gathered with
Victor Sordillo (Mayor, Warren NJ), Lisa Lontai (Deputy Mayor,
Warren NJ), Raymond Giacobbe (Mayor, Rahway NJ), Susan McCartney
(Mayor, West Orange NJ), Matthew Moench (Mayor, Bridgewater NJ),
Andrew McNally (Mayor, Bernards NJ), Robert Parisi (Former Mayor,
West Orange NJ), Tammy Williams (Councilwoman, West Orange NJ),
Sara Sooy (Deputy Director, Warren NJ), Douglas Singleterry
(Commissioner of Somerset County), and U.S. Congressmen Josh
Gottheimer and Robert Menendez. The event also included the
nation’s first responders including Matthew Caliente (President of
Professional Firefighters Association Of New Jersey and Long COVID
patient advocate) and Robert Ferreiro (Warren County Chief of
Police), aiming to understand patients' needs and discuss how the
Tevogen model could reduce healthcare costs and improve patient
outcomes.
"We are honored by the widespread interest in Tevogen's business
model from all sectors of society and express our gratitude to all
attendees, especially the patients who shared their stories,"
remarked Dr. Ryan Saadi, founding CEO of Tevogen Bio.
About Tevogen Bio
Tevogen is a clinical-stage specialty immunotherapy company
harnessing one of nature’s most powerful immunological weapons,
CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically
unmodified precision T cell therapies for the treatment of
infectious diseases, cancers, and neurological disorders, aiming to
address the significant unmet needs of large patient populations.
Tevogen Leadership believes that sustainability and commercial
success in the current era of healthcare rely on ensuring patient
accessibility through advanced science and innovative business
models. Tevogen has reported positive safety data from its
proof-of-concept clinical trial, and its key intellectual property
assets are wholly owned by the company, not subject to any
third-party licensing agreements. These assets include three
granted patents and twelve pending patents, two of which are
related to artificial intelligence.
Contacts
Tevogen Bio CommunicationsT: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com
Tevogen Bio (NASDAQ:TVGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Tevogen Bio (NASDAQ:TVGN)
Historical Stock Chart
From Sep 2023 to Sep 2024